Off-Label Use of Atypical Antipsychotics: An Update
Summary of Adverse Effects in Adults (1 of 2)
Antipsychotics in the atypical class generally promote weight gain in adults (ages 18–64) and in the elderly (ages ≥65), but olanzapine is associated with greater risk than typical or other atypical antipsychotics. For olanzapine, the number needed to harm is 3 versus 16–35 for other atypical antipsychotics.
Some atypical antipsychotics (olanzapine in particular) are associated with endocrine and metabolic abnormalities, but the degree of increased risk is not clear.
Keywords: atypical antipsychotics | endocrine | metabolic | off-label | olanzapine | second generation | weight | antipsychotics
- Maglione M, Ruelaz Maher A, Hu J, et al. Off-Label Use of Atypical Antipsychotics: An Update. Comparative Effectiveness Review No. 43 (Prepared by the Southern California RAND Evidence-based Practice Center under Contract No. HHSA 290-2007-10062-I). Rockville, MD: Agency for Healthcare Research and Quality; September 2011. AHRQ Publication No. 11(12)-EHC087-EF. Available at www.effectivehealthcare.ahrq.gov/offlabelantipsych.cfm.
Your slide tray is being processed.